Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 14/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1497274 | 0.92 | ADORA2B (0.49) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1497279 | 0.88 | ADORA2B (0.57) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1497268 | 0.87 | ADORA2B (0.55) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1497271 | 0.84 | ADORA2B (0.68) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1497247 | 0.84 | ADORA2B (0.53) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1497219 | 0.82 | ADORA2B (0.64) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1242172 | 0.82 | ADORA2B (0.57) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1497756 | 0.82 | ADORA2B (0.55) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1497249 | 0.82 | ADORA2B (0.62) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1497221 | 0.81 | ADORA2B (0.62) | ADORA2BADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | claimed |
| EP-1658291-A2 | SUBSTITUTED 8-HETEROARYL XANTHINES | Adenosine Therapeutics, LLC (US) | 2006-05-24 | — | — | EP | claimed |
| US-20050065341-A1 | Substituted 8-heteroaryl xanthines | ALLERGAN SALES, LLC | 2005-03-24 | — | — | US | claimed |
| WO-2005021548-A2 | SUBSTITUTED 8-HETEROARYL XANTHINES | ADENOSINE THERAPEUTICS, LLC (US) | 2005-03-10 | — | — | WO | claimed |
| EP-2295434-B1 | Substituted 8-heteroaryl xanthines | DOGWOOD PHARMACEUTICALS INC (US) | 2015-09-30 | — | — | EP | disclosed |
| EP-1658291-B1 | SUBSTITUTED 8-HETEROARYL XANTHINES | DOGWOOD PHARMACEUTICALS INC (US) | 2013-10-02 | — | — | EP | disclosed |
| CN-101851238-B | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS LLC | 2012-07-18 | — | — | CN | disclosed |
| EP-2295434-A2 | Substituted 8-heteroaryl xanthines | Adenosine Therapeutics, LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | PGXHEALTH, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-7732455-B2 | Substituted 8-heteroaryl xanthines | PGX HEALTH, LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ALLERGAN SALES, LLC | 2008-08-21 | — | — | US | disclosed |
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1658291-A2 | SUBSTITUTED 8-HETEROARYL XANTHINES | Adenosine Therapeutics, LLC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20050065341-A1 | Substituted 8-heteroaryl xanthines | ALLERGAN SALES, LLC | 2005-03-24 | — | — | US | disclosed |
| WO-2005021548-A2 | SUBSTITUTED 8-HETEROARYL XANTHINES | ADENOSINE THERAPEUTICS, LLC (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 4/4885 |
| US-20050065341-A1 | Substituted 8-heteroaryl xanthines | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 4/4885 |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.